NCT00479713View on ClinicalTrials.gov

A Study to Assess the Cholesterol Lowering Effect of an Ezetimibe/Simvastatin Combination Tablet Compared to Another Cholesterol Lowering Drug in Patients With High Cholesterol and With High Cardiovascular Risk (0653A-809)(COMPLETED)

PHASE3CompletedINTERVENTIONAL

Enrollment

618

Participants

Timeline

Start Date

February 1, 2007

Primary Completion Date

March 1, 2008

Study Completion Date

March 1, 2008

Conditions

Hypercholesterolemia

Interventions

DRUG

ezetimibe (+) simvastatin

ezetimibe/simvastatin 10/20mg. The treatment duration will be 6 weeks.

DRUG

Comparator : rosuvastatin calcium

rosuvastatin 10mg. The treatment duration will be 6 weeks.

DRUG

Comparator: Placebo (unspecified)

rosuvastatin 10mg Placebo. The treatment duration will be 6 weeks.

DRUG

Comparator: Placebo (unspecified)

ezetimibe/simvastatin 10/20mg Placebo. The treatment duration will be 6 weeks.

All Listed Sponsors

lead

Organon and Co

INDUSTRY

NCT00479713 - A Study to Assess the Cholesterol Lowering Effect of an Ezetimibe/Simvastatin Combination Tablet Compared to Another Cholesterol Lowering Drug in Patients With High Cholesterol and With High Cardiovascular Risk (0653A-809)(COMPLETED) | Biotech Hunter | Biotech Hunter